Patients and donor characteristics, GVHD prophylaxis, and (tetramer-positive) T cells
Patient . | . | . | Donor . | . | GVHD prophylaxis . | . | . | CD8+ T cells, 3 mo* . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Diagnosis . | Age, y . | HLA match . | CMV . | Graft . | Immunosuppression . | GVHD grade . | CD8+ . | Tet+ . | ||||||
| 1 | CLL | 47 | idsib | + | Re | CyA/MTX | 0 | 1147 | 48 | ||||||
| 2 | My | 38 | idsib | + | Re | CyA/MTX | 1 | 351 | 15 | ||||||
| 3 | AML | 49 | idsib | + | De | CyA | 0 | 567 | 58 | ||||||
| 4 | ALL | 36 | mmrd | + | De | CyA | 0 | 432 | 8 | ||||||
| 5 | AML | 35 | idsib | + | De | CyA | 0 | 1365 | 31 | ||||||
| 6 | My | 24 | idsib | + | De | CyA | 0 | 85 | 3 | ||||||
| 7 | AA | 31 | idsib | + | De | CyA | 0 | 269 | 6 | ||||||
| 8 | MDS | 44 | idsib | + | De | CyA | 0 | 407 | 65 | ||||||
| 9 | Ly | 30 | idsib | + | De | CyA | 0 | 193 | 25 | ||||||
| 10 | My | 43 | idsib | + | De | CyA | 2 | 372 | 9 | ||||||
| 11 | My | 40 | idsib | – | Re | CyA/MTX | 0 | 480 | 0 | ||||||
| 12 | AML | 44 | mud | – | Re | CyA | 0 | 302 | 0 | ||||||
| 13 | Ly | 61 | idsib | – | Re | CyA/MM | 1 | 1925 | 198 | ||||||
| 14 | AML | 34 | idsib | – | Re | CyA/MTX | 1 | 55 | 0 | ||||||
| 15 | CML | 36 | idsib | – | Re | CyA/MTX | 1 | 950 | 0 | ||||||
| 16 | AML | 47 | idsib | – | De | CyA | 0 | 243 | 9 | ||||||
| 17 | ALL | 36 | idsib | – | De | CyA | 0 | 1188 | 95 | ||||||
Patient . | . | . | Donor . | . | GVHD prophylaxis . | . | . | CD8+ T cells, 3 mo* . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Diagnosis . | Age, y . | HLA match . | CMV . | Graft . | Immunosuppression . | GVHD grade . | CD8+ . | Tet+ . | ||||||
| 1 | CLL | 47 | idsib | + | Re | CyA/MTX | 0 | 1147 | 48 | ||||||
| 2 | My | 38 | idsib | + | Re | CyA/MTX | 1 | 351 | 15 | ||||||
| 3 | AML | 49 | idsib | + | De | CyA | 0 | 567 | 58 | ||||||
| 4 | ALL | 36 | mmrd | + | De | CyA | 0 | 432 | 8 | ||||||
| 5 | AML | 35 | idsib | + | De | CyA | 0 | 1365 | 31 | ||||||
| 6 | My | 24 | idsib | + | De | CyA | 0 | 85 | 3 | ||||||
| 7 | AA | 31 | idsib | + | De | CyA | 0 | 269 | 6 | ||||||
| 8 | MDS | 44 | idsib | + | De | CyA | 0 | 407 | 65 | ||||||
| 9 | Ly | 30 | idsib | + | De | CyA | 0 | 193 | 25 | ||||||
| 10 | My | 43 | idsib | + | De | CyA | 2 | 372 | 9 | ||||||
| 11 | My | 40 | idsib | – | Re | CyA/MTX | 0 | 480 | 0 | ||||||
| 12 | AML | 44 | mud | – | Re | CyA | 0 | 302 | 0 | ||||||
| 13 | Ly | 61 | idsib | – | Re | CyA/MM | 1 | 1925 | 198 | ||||||
| 14 | AML | 34 | idsib | – | Re | CyA/MTX | 1 | 55 | 0 | ||||||
| 15 | CML | 36 | idsib | – | Re | CyA/MTX | 1 | 950 | 0 | ||||||
| 16 | AML | 47 | idsib | – | De | CyA | 0 | 243 | 9 | ||||||
| 17 | ALL | 36 | idsib | – | De | CyA | 0 | 1188 | 95 | ||||||
CLL indicates chronic lymphocytic leukemia; idsib, HLA-identical sibling; Re, T-cell replete; CyA, cyclosporin A; MTX, methotrexate; My, multiple myeloma; AML, acute myeloid leukemia; De, T-cell depleted; ALL, acute lymphoblastic leukemia; mmrd, mismatched family donor; AA, severe aplastic anemia; MDS, myelodysplastic syndrome; Ly, lymphoma; mud, unrelated donor matched by high-resolution typing; MM, mycophenolate mofetil.
Number of CD8+ or tetramer-positive (Tet+) cells/mL in the blood sample at 3 months (85 ± 30 days) after transplantation